Analysts Set Icon Plc (NASDAQ:ICLR) Target Price at $207.14

Shares of Icon Plc (NASDAQ:ICLR) have received an average recommendation of “Moderate Buy” from the twenty ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, nine have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $207.1429.

A number of equities research analysts recently issued reports on the stock. TD Cowen decreased their price target on shares of Icon from $183.00 to $172.00 and set a “hold” rating on the stock in a research note on Friday, October 24th. UBS Group set a $220.00 price target on shares of Icon in a research note on Friday, October 24th. Jefferies Financial Group downgraded shares of Icon from a “buy” rating to a “hold” rating and lowered their price target for the company from $220.00 to $175.00 in a report on Tuesday, September 9th. Leerink Partners set a $220.00 price target on shares of Icon in a report on Thursday, October 23rd. Finally, Truist Financial increased their price target on shares of Icon from $187.00 to $234.00 and gave the company a “buy” rating in a report on Friday, July 25th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ICLR. Vanguard Personalized Indexing Management LLC increased its position in Icon by 49.0% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 2,571 shares of the medical research company’s stock valued at $450,000 after acquiring an additional 845 shares during the last quarter. Parthenon LLC increased its position in Icon by 28.7% during the third quarter. Parthenon LLC now owns 79,785 shares of the medical research company’s stock valued at $13,962,000 after acquiring an additional 17,815 shares during the last quarter. Sector Gamma AS bought a new position in Icon during the third quarter valued at $4,369,000. CIBC Asset Management Inc increased its position in Icon by 42.2% during the third quarter. CIBC Asset Management Inc now owns 2,064 shares of the medical research company’s stock valued at $361,000 after acquiring an additional 613 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in Icon during the third quarter valued at $1,342,000. Institutional investors own 95.61% of the company’s stock.

Icon Price Performance

ICLR stock opened at $171.82 on Wednesday. Icon has a one year low of $125.10 and a one year high of $231.89. The company’s fifty day moving average price is $178.16 and its 200-day moving average price is $159.59. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The company has a market capitalization of $13.88 billion, a PE ratio of 23.25, a price-to-earnings-growth ratio of 3.04 and a beta of 1.23.

Icon (NASDAQ:ICLR) last released its earnings results on Wednesday, October 22nd. The medical research company reported $3.31 EPS for the quarter, topping the consensus estimate of $3.28 by $0.03. Icon had a net margin of 7.40% and a return on equity of 10.58%. The firm had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $1.98 billion. During the same quarter in the previous year, the firm earned $3.35 earnings per share. The company’s quarterly revenue was up .6% compared to the same quarter last year. On average, equities analysts anticipate that Icon will post 13.38 EPS for the current fiscal year.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.